vs
Side-by-side financial comparison of Primis Financial Corp. (FRST) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $45.6M, roughly 1.3× Primis Financial Corp.).
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
FRST vs PHAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $45.6M | $57.6M |
| Net Profit | $7.3M | — |
| Gross Margin | — | 86.7% |
| Operating Margin | — | — |
| Net Margin | 16.0% | — |
| Revenue YoY | — | 94.1% |
| Net Profit YoY | 200.0% | 71.6% |
| EPS (diluted) | $0.30 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.6M | — | ||
| Q4 25 | $80.9M | $57.6M | ||
| Q3 25 | $41.0M | $49.5M | ||
| Q2 25 | $43.2M | $39.5M | ||
| Q1 25 | $58.7M | $28.5M | ||
| Q4 24 | $38.8M | $29.7M | ||
| Q3 24 | $37.3M | $16.4M | ||
| Q2 24 | $35.7M | $7.3M |
| Q1 26 | $7.3M | — | ||
| Q4 25 | $29.5M | — | ||
| Q3 25 | $6.8M | $-30.0M | ||
| Q2 25 | $2.4M | $-75.8M | ||
| Q1 25 | $22.6M | $-94.3M | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $1.2M | $-85.6M | ||
| Q2 24 | $3.4M | $-91.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | — | ||
| Q3 25 | 21.3% | -30.8% | ||
| Q2 25 | 6.9% | -151.7% | ||
| Q1 25 | 41.9% | -276.5% | ||
| Q4 24 | -123.0% | — | ||
| Q3 24 | -3.1% | -433.0% | ||
| Q2 24 | 7.8% | -1055.4% |
| Q1 26 | 16.0% | — | ||
| Q4 25 | 36.5% | — | ||
| Q3 25 | 16.7% | -60.5% | ||
| Q2 25 | 5.6% | -191.9% | ||
| Q1 25 | 38.6% | -330.7% | ||
| Q4 24 | -100.3% | — | ||
| Q3 24 | 3.3% | -523.3% | ||
| Q2 24 | 9.6% | -1248.6% |
| Q1 26 | $0.30 | — | ||
| Q4 25 | $1.19 | — | ||
| Q3 25 | $0.28 | $-0.41 | ||
| Q2 25 | $0.10 | $-1.05 | ||
| Q1 25 | $0.92 | $-1.31 | ||
| Q4 24 | $-0.95 | — | ||
| Q3 24 | $0.05 | $-1.32 | ||
| Q2 24 | $0.14 | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $159.9M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $427.2M | $-438.2M |
| Total Assets | $4.3B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $159.9M | — | ||
| Q4 25 | $143.6M | $130.0M | ||
| Q3 25 | $63.9M | $135.2M | ||
| Q2 25 | $94.1M | $149.6M | ||
| Q1 25 | $57.0M | $212.3M | ||
| Q4 24 | $64.5M | $297.3M | ||
| Q3 24 | $77.3M | $334.7M | ||
| Q2 24 | $66.6M | $276.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M |
| Q1 26 | $427.2M | — | ||
| Q4 25 | $422.9M | $-438.2M | ||
| Q3 25 | $382.2M | $-422.5M | ||
| Q2 25 | $376.4M | $-405.8M | ||
| Q1 25 | $375.6M | $-338.4M | ||
| Q4 24 | $351.8M | $-253.6M | ||
| Q3 24 | $381.0M | $-187.1M | ||
| Q2 24 | $376.0M | $-233.8M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.0B | $259.1M | ||
| Q3 25 | $4.0B | $240.3M | ||
| Q2 25 | $3.9B | $250.2M | ||
| Q1 25 | $3.7B | $294.2M | ||
| Q4 24 | $3.7B | $378.3M | ||
| Q3 24 | $4.0B | $387.0M | ||
| Q2 24 | $4.0B | $319.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $10.8M | $-166.8M | ||
| Q3 25 | $-11.4M | $-14.1M | ||
| Q2 25 | $-41.0M | $-62.7M | ||
| Q1 25 | $34.4M | $-84.9M | ||
| Q4 24 | $19.5M | $-266.8M | ||
| Q3 24 | $6.1M | $-63.6M | ||
| Q2 24 | $52.3M | $-70.7M |
| Q1 26 | — | — | ||
| Q4 25 | $9.0M | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | $18.3M | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.2% | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | 47.3% | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | — | -966.2% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 3.1% | 0.5% | ||
| Q3 24 | 0.0% | 0.3% | ||
| Q2 24 | 0.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.36× | — | ||
| Q3 25 | -1.67× | — | ||
| Q2 25 | -16.82× | — | ||
| Q1 25 | 1.52× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.93× | — | ||
| Q2 24 | 15.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
PHAT
Segment breakdown not available.
